Business
Final results for the year ended 31 December 2025
Proteome Sciences plc reported a decrease in total revenues to £3.76 million for the year ended December 31, 2025, down from £4.89 million in 2024, primarily due to a significant drop in TMT® reagent sales and royalties to £1.70 million from £4.01 million. However, proteomic services revenue more than doubled to £2.06 million from £0.87 million. The company posted a loss after tax of £3.06 million, an improvement from £3.41 million in the prior year, with cash reserves at £0.78 million. Despite the revenue decline, the company views 2025 as the bottom of its business cycle and is optimistic about future growth driven by its services business and a projected recovery in TMT® reagent sales. Disclaimer*
About this update from Proteome Sciences Plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. 15 April 2026 Proteome Sciences plc ("Proteome Sciences" the "Company" or the "Group") Final results for the year ended 31 December 2025 The Company is pleased to announce its audited results for the year ended 31 December 2025. Highlights: · Total revenues of £3.76m (2024: £4.89m) · Proteomic services revenues of £2.06m (2024: £0.87m) · TMT® reagent sales, and royalties of £1.70m (2024: £4.01m) · Loss after tax £3.06m (2024: £3.41m) · Cash at year end £0.78m (2024: £1.13m) · Cost of sales and administrative costs £6.42m (2024: £7.24m) · Adjusted EBITDA* loss of £1.72m (2024: loss of £1.48m) * EBITDA is a non-GAAP company specific measure which is considered to be a key performance indicator of the Group's financial performance. Adjusted EBITDA is calculated as operating profit before depreciation (including right-to-use assets amortisation), amortisation, non-recurring costs, and employee share-based payment. Executive Chairman of Proteome Sciences plc, commented: "After the significant investment previously made in additional capacity, staffing, the San Diego facility and the recent fund raising, we consider that 2025 was the bottom of the cycle for our business. We are optimistic with this behind us that we are well positioned to deliver substantial increases and returns from the wider combination of our activities and exposure in proteomics with good growth expected to continue from our services business and a recovery in TMT® reagents sales from the cuts imposed on US NIH (National Institutes of Health) budgets in 2025." Report and Accounts and Notice of Annual General Meeting: Copies of the Annual Report and Accounts together with notice of the Annual General Meeting ("AGM") will be posted to shareholders shortly and made availab...
View stock analysis, news, and events for Proteome Sciences Plc